Similar to aging, cancer is a state where cells lose their original identity. By applying age-reversal technologies, cancer cells can be forced to become normal again or even self-destruct, offering a novel approach to cancer treatment.

Step Pharma's synthetic lethality approach targets two redundant enzymes in the same pathway. Deleting one makes cancer cells entirely dependent on the other. This direct dependency is harder for biology to circumvent compared to approaches targeting different, interconnected pathways, creating a "cleaner" kill mechanism.

By simultaneously targeting dozens of functionally unrelated survival genes across different chromosomes, Nuago's therapy makes it statistically improbable for cancer cells to mutate and develop escape routes. This multi-pronged attack from a single drug construct is a core advantage over therapies that cancer can evolve around.

Cancer cells down-regulate microRNAs to enable growth. This biological shift creates an opening for Nuago's therapy to access the cell's machinery. Healthy cells, with high microRNA expression, naturally block the therapy. This provides inherent selectivity, a huge therapeutic window, and minimal toxicity by design of fundamental biology.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Targeting GSPT1 is highly effective because its degradation disrupts the production of a specific subset of proteins critical to cancer. This simultaneously reduces levels of key drivers like MYC, androgen receptor (AR), and Cyclin D1, creating a powerful multi-target effect from a single drug.

The therapy’s targets are fundamental survival genes conserved from worms to humans. This deep biological foundation makes the treatment 'cancer-agnostic,' effective regardless of tumor origin, subtype, or the patient's genetic background. The company has successfully killed 66 different tumor types across seven species.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

Unlike conventional treatments, Nuago's therapy is more effective against highly aggressive, late-stage tumors. The very biological traits that define aggressiveness—loss of microRNAs and upregulation of survival genes—are the exact vulnerabilities Nuago's platform exploits, making the most dangerous cancers the most responsive to treatment.